These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23786757)

  • 1. Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade.
    Zhu DW; Liu Y; Yang X; Yang CZ; Ma J; Yang X; Qiao JK; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
    BMC Cancer; 2013 Jun; 13():301. PubMed ID: 23786757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
    Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
    Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
    Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
    J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
    Zhong LP; Zhu DW; William WN; Liu Y; Ma J; Yang CZ; Yang X; Wang LZ; Li J; Myers JN; Lee JJ; Zhang CP; Zhang ZY
    Mol Cancer Ther; 2013 Jun; 12(6):1112-21. PubMed ID: 23515614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
    Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Wang LZ; Fan XD; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Wang BS; Kies MS; Lee JJ; Myers JN; Zhang ZY
    J Clin Oncol; 2013 Feb; 31(6):744-51. PubMed ID: 23129742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
    Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
    Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
    Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
    Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospholipase C gamma 1 is a potential prognostic biomarker for patients with locally advanced and resectable oral squamous cell carcinoma.
    Zhu D; Tan Y; Yang X; Qiao J; Yu C; Wang L; Li J; Zhang Z; Zhong L
    Int J Oral Maxillofac Surg; 2014 Dec; 43(12):1418-26. PubMed ID: 25085076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stathmin guides personalized therapy in oral squamous cell carcinoma.
    Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
    Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of Annexin A1 correlates with pathologic differentiation grade in oral squamous cell carcinoma.
    Zhang L; Yang X; Zhong LP; Zhou XJ; Pan HY; Wei KJ; Li J; Chen WT; Zhang ZY
    J Oral Pathol Med; 2009 Apr; 38(4):362-70. PubMed ID: 18673418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
    Wen J; Xu H; Liu R; Chen Q; Dai Y; Xu Y
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):24-31. PubMed ID: 32538743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Annexin A1 down-regulation in oral squamous cell carcinoma correlates to pathological differentiation grade.
    Zhu DW; Yang X; Yang CZ; Ma J; Liu Y; Yan M; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
    Oral Oncol; 2013 Jun; 49(6):542-50. PubMed ID: 23403091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated growth differentiating factor 15 expression predicts long-term benefit of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy in patients with oral cancer.
    Tang X; Hu YJ; Ju WT; Fu Y; Sun WW; Liu Y; Tan YR; Wang LZ; Li J; Tu YY; Zhang CP; Zhang ZY; Zhong LP
    Oncol Lett; 2018 May; 15(5):8118-8124. PubMed ID: 29731919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer.
    Inhestern J; Oertel K; Stemmann V; Schmalenberg H; Dietz A; Rotter N; Veit J; Görner M; Sudhoff H; Junghanß C; Wittekindt C; Pachmann K; Guntinas-Lichius O
    PLoS One; 2015; 10(7):e0132901. PubMed ID: 26186556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.
    Luo SD; Chen YJ; Liu CT; Rau KM; Chen YC; Tsai HT; Chen CH; Chiu TJ
    Biomed Res Int; 2015; 2015():508587. PubMed ID: 26491674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
    Ren G; Ju H; Wu Y; Song H; Ma X; Ge M; Qiu W; Chen Y; He Y; Zhuang Q; Meng J; Guo W
    Int J Hyperthermia; 2021; 38(1):939-947. PubMed ID: 34134574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of topical ALA-photodynamic therapy combined with induction chemotherapy for locally advanced oral squamous cell carcinoma.
    Wang X; Li N; Meng J; Wen N
    Am J Otolaryngol; 2021; 42(6):103112. PubMed ID: 34214712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
    Oertel K; Spiegel K; Schmalenberg H; Dietz A; Maschmeyer G; Kuhnt T; Sudhoff H; Wendt TG; Guntinas-Lichius O
    BMC Cancer; 2012 Oct; 12():483. PubMed ID: 23083061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
    Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Owonikoko TK; Sarlis NJ; Eggers C; Phelan V; Grist WJ; Chen AY; Ramalingam SS; Chen ZG; Beitler JJ; Shin DM; Khuri FR; Marcus AI
    Head Neck Pathol; 2014 Mar; 8(1):66-72. PubMed ID: 23881549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
    Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
    Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.